PCVX — Vaxcyte, Inc. stock price, charts and financials

QT70Vaxcyte, Inc.

Vaxcyte, Inc. (NASDAQ: PCVX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
53.53
-0.55-1.02%
OverviewShort InterestFilings
PCVXQT70Vaxcyte, Inc.·NASDAQ
53.53-1.02%
Earnings
Down 1.0% — Earnings due 2026-08-05 — pre-report positioning.
Medium confidence
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
IMVT-0.28%$38.51TGTX-11.26%$46.17IBRX-0.28%$7.15ALKS+1.10%$49.53APGE+0.01%$134.11KYMR-2.99%$100.31SYRE-3.46%$94.93PRAX-0.75%$305.51
Snapshot
Index-P/E-EPS (ttm)-Insider Own0.86%Shs Outstand144.40MPerf Week-1.06%
Market Cap7.81BForward P/E-EPS next Y-6.69Insider Trans-8.62%Shs Float132.08MPerf Month-3.57%
Enterprise Value7.66BPEG0.17EPS next Q-Inst Own-Short Float10.78%Perf Quarter-5.52%
Income-980.03MP/S0.00EPS this Y-Inst Trans-Short Ratio8.93Perf Half Y2.39%
Sales0.00P/B2.52EPS next Y20.20%ROA-28.27%Short Interest14.23MPerf YTD17.21%
Book/sh-P/C-EPS next 5Y-ROE-32.51%52W High64.34 -16.80%Perf Year55.31%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-34.98%52W Low28.78 85.97%Perf 3Y14.87%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility5.31% 4.40%Perf 5Y140.14%
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-81.05%Oper. Margin0.00%ATR (14)2.52Perf 10Y-
Dividend Ex-Date-Quick Ratio7.49Sales Y/Y TTM-Profit Margin0.00%RSI (14)46.92Recom2.00
Dividend Gr. 3/5Y-Current Ratio7.49EPS Q/Q-121.15%SMA20-4.25%Beta1.22Target Price89.00
Payout0.00%Debt/Eq0.04Sales Q/Q-SMA502.15%Rel Volume0.50Prev Close54.08
Employees507LT Debt/Eq0.08EarningsAug 05SMA2003.89%Avg Volume1.57MPrice53.53
IPO DateJun 12, 2020Option/ShortYes / YesEPS/Sales Surpr.-29.40% -Net Debt/EBITDA0.16Volume793,219Change-1.02%
Analyst Ratings
DateActionAnalystRatingTarget
Nov-19-25ReiteratedLeerink PartnersOutperform$135 → $77
Nov-06-24ReiteratedJefferiesBuy$129 → $146
Nov-06-24ReiteratedLeerink PartnersOutperform$153 → $135
Sep-10-24ReiteratedMizuhoOutperform$113 → $163
Sep-04-24ReiteratedBank of America Securities$101 → $140
Sep-03-24ReiteratedMizuho SecuritiesBuy$113
Sep-03-24ReiteratedLeerink PartnersOutperform$60 → $153
Sep-03-24ReiteratedBTIGBuy$98 → $160
Sep-03-24ReiteratedJefferiesBuy$129
Aug-07-24ReiteratedBTIGBuy$69 → $98
Latest News
Company

Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
FY 2017
12/31/2017
Total Revenue
000000000
Cost of Goods Sold Incl. D&A000001110
Gross Profit00000-1-1-10
Selling, General and Administrative Excl. Other1299361402515755
Research and Development7944773321697874463013
Other Operating Expense1075231-101-1
Operating Income-924-570-468-232-104-90-54-36-18
Interest Expense
000000000
Unusual Expense
—————————
Non-Operating Income (Expense)15710666940461
Net Income Before Taxes-767-464-402-223-100-89-50-29-17
Income Taxes
000000000
Consolidated Net Income-767-464-402-223-100-89-50-29-17
Net Income From Continuing Operations-767-464-402-223-100-89-50-29-17
Net Income-767-464-402-223-100-89-50-29-17
EPS (Recurring)-5.63-3.80-4.14-3.44-1.93-2.97-14.10-8.12-4.84
EPS (Basic, Before Extraordinaries)-5.63-3.80-4.14-3.44-1.93-2.97-14.10-8.12-4.84
EPS (Diluted)-5.63-3.80-4.14-3.44-1.93-2.97-14.10-8.12-4.83
EBITDA-742-448-392-214-97-88-49-28-17
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio
—————————
Gross Margin
—————————
Operating Margin
—————————
Net Margin
—————————
Shares Outstanding13612297655230444
Market Capitalization6,2759,9876,0923,1171,237797———
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$68.05$57.20$46.36$35.51$24.66● Close Price0.00M0.77M1.55M2.32M3.10MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
PICKERING GRANTCHIEF EXECUTIVE OFFICERJul 27 '26Sale55.6318,1981,012,374133,215Jul 28
PICKERING GRANTCHIEF EXECUTIVE OFFICERJul 27 '26Option Exercise2.0316,19832,882469,445Jul 28
GUGGENHIME ANDREWPRESIDENT AND CFOJul 06 '26Sale57.2810,000572,836104,395Jul 06
GUGGENHIME ANDREWPRESIDENT AND CFOJul 06 '26Option Exercise5.3510,00053,500114,395Jul 06
Wassil JimCHIEF OPERATING OFFICERJul 01 '26Sale56.332,250126,737156,760Jul 06
Wassil JimCHIEF OPERATING OFFICERJul 01 '26Option Exercise5.355162,761159,010Jul 06
PICKERING GRANTCHIEF EXECUTIVE OFFICERJun 26 '26Sale55.2224,2371,338,270134,215Jun 26
PICKERING GRANTCHIEF EXECUTIVE OFFICERJun 18 '26Option Exercise1.79225403497,164Jun 18
PICKERING GRANTCHIEF EXECUTIVE OFFICERJun 18 '26Sale52.5023,4611,231,705135,215Jun 18
GUGGENHIME ANDREWPRESIDENT AND CFOJun 18 '26Option Exercise5.3510,00053,500114,395Jun 18
GUGGENHIME ANDREWPRESIDENT AND CFOJun 18 '26Sale53.0010,000530,000104,395Jun 18
Wassil JimCHIEF OPERATING OFFICERMay 01 '26Sale56.832,250127,870160,744May 01
Cowan ElviaSVP, Finance & CAOApr 07 '26Option Exercise25.923,00077,76031,975Apr 08
Cowan ElviaSVP, Finance & CAOApr 07 '26Sale60.003,000180,00028,975Apr 08
Wassil JimCHIEF OPERATING OFFICERApr 01 '26Sale58.432,250131,476162,994Apr 03
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.